Nexien BioPharma, Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was USD 0.361902 million compared to USD 0.626357 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0168 USD | -17.04% | -42.07% | -35.14% |
1st Jan change | Capi. | |
---|---|---|
-35.14% | 1.13M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- NXEN Stock
- News Nexien BioPharma, Inc.
- Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023